HOME > ARCHIVE

ARCHIVE

OTC NEWS IN BRIEF

March 29, 2004
MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF

March 22, 2004
REGULATORY NEWS IN BRIEF

March 22, 2004
Impact of NHI Price Revisions Ranges from 3% to 7%

March 22, 2004
CORPORATE ROUNDUP NEWS IN BRIEF

March 22, 2004
New NHI Prices Gazetted on March 5

March 22, 2004
BUSINESS NEWS IN BRIEF

March 22, 2004
Japan CRO Association Holds 10th Anniversary Symposium

March 22, 2004
Novartis Has 58 Products in PII, PIII in US: CEO Ebeling

March 22, 2004
Meet the Leaders (31)

March 22, 2004
Banyu to "Seriously Go After the Japanese Market": Mr Hirate

March 22, 2004
Annual Business Results

March 22, 2004
Aiming to Be a "Global Mega-player" via Merger: Dr Aoki of Fujisawa

March 22, 2004
WORLD NEWS IN BREIF

March 22, 2004
Eisai Seeks Efficiency, Not Scale: Mr Naito

March 22, 2004
DIAGNOSTIC NEWS IN BRIEF

March 22, 2004
Pfizer Japan Aims to Boost MR Productivity by 50% in 5 Years: Mr Bootes

March 22, 2004
OTC NEWS IN BRIEF

March 22, 2004
BULLETIN

March 22, 2004
MEDICAL DEVICE NEWS IN BRIEF

March 22, 2004

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises

By Hayate Horiguchi

Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…